AstraZeneca (LSE:AZN) reported positive Phase III data for three cancer medicines at the ESMO Congress 2026 on 23 October. Sonesitatug vedotin (Sone Ve) showed statistically significant survival benefits in advanced gastric and gastroesophageal junction cancer.

Oct 21 (Reuters) - AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment for adults with immunoglobulin A nephropathy, a rare kidney disease that can lead to renal failure.

Oct 20 () - Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease ‌remission in 69% of patients with a type of chronic ‌inflammatory

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.

AstraZeneca (AZN) on Thursday announced an AI-driven drug discovery and licensing deal worth up to $1.5B with California-based insitro, the Anglo-Swedish drugmaker’s latest partnership in the U.S. As part of the deal, the companies will jointly identify ...

AstraZeneca has partnered with AI biotech insitro to identify drug targets and develop potential treatments for MASH, a serious liver disease, and cardiomyopathies. AstraZeneca will pay $40 million upfront,

AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology market.